Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients

The transcription factor Forkhead box M1 (FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2011-11, Vol.17 (21), p.6791-6801
Hauptverfasser: PRILLER, Markus, PÖSCHL, Julia, ABRAO, Leticia, VON BUEREN, André O, CHO, Yoon-Jae, RUTKOWSKI, Stefan, KRETZSCHMAR, Hans A, SCHÜLLER, Ulrich
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 6801
container_issue 21
container_start_page 6791
container_title Clinical cancer research
container_volume 17
creator PRILLER, Markus
PÖSCHL, Julia
ABRAO, Leticia
VON BUEREN, André O
CHO, Yoon-Jae
RUTKOWSKI, Stefan
KRETZSCHMAR, Hans A
SCHÜLLER, Ulrich
description The transcription factor Forkhead box M1 (FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P = 0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. FoxM1 may be used as an additional prognostic marker and may represent a potential novel target to treat patients suffering from medulloblastoma.
doi_str_mv 10.1158/1078-0432.ccr-11-1214
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902085802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>902085802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-af8954509345b45dcfacb7b011cf2a29d3f8e53b3d9cd42a211df62e0a593f933</originalsourceid><addsrcrecordid>eNpFkEtP3TAQRi0EAgr9CSBvUFehHj9IvKwiaK8EKqJFXVqOHyLIN754Eh7_vom4tKsZjc43MzqEnAA7B1DNV2B1UzEp-LlzpQKogIPcIYegVF0JfqF25_6DOSCfEB8ZAwlM7pMDDhoaqPkhebl83ZSA2OeB5kiv8usN0BXSu_A09SV4GnOh40OgtyWnPoZixy16E_yUUu6SxTGvLW1DSkjt4Olq8L2zY0D6JxcM9NdUnvtnm5bU7ZwPw4jHZC_ahOHzth6R-6vL3-2P6vrn91X77bpyUsFY2dhoJRXTQqpOKu-idV3dMQAXueXai9gEJTrhtfNyngD4eMEDs0qLqIU4Il_e925KfpoCjmbdo5tftUPIExrNOGtUw_hMqnfSlYxYQjSb0q9teTPAzKLcLDrNotO07d08MovyOXe6vTB16-D_pT4cz8DZFrDobIrFDq7H_5ysuQTNxV-3J4sI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>902085802</pqid></control><display><type>article</type><title>Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>PRILLER, Markus ; PÖSCHL, Julia ; ABRAO, Leticia ; VON BUEREN, André O ; CHO, Yoon-Jae ; RUTKOWSKI, Stefan ; KRETZSCHMAR, Hans A ; SCHÜLLER, Ulrich</creator><creatorcontrib>PRILLER, Markus ; PÖSCHL, Julia ; ABRAO, Leticia ; VON BUEREN, André O ; CHO, Yoon-Jae ; RUTKOWSKI, Stefan ; KRETZSCHMAR, Hans A ; SCHÜLLER, Ulrich</creatorcontrib><description>The transcription factor Forkhead box M1 (FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P = 0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. FoxM1 may be used as an additional prognostic marker and may represent a potential novel target to treat patients suffering from medulloblastoma.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.ccr-11-1214</identifier><identifier>PMID: 21918172</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adolescent ; Adult ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - biosynthesis ; Biomarkers, Tumor - genetics ; Cell Growth Processes - physiology ; Cell Line, Tumor ; Cerebellar Neoplasms - genetics ; Cerebellar Neoplasms - metabolism ; Cerebellar Neoplasms - pathology ; Child ; Child, Preschool ; Forkhead Box Protein M1 ; Forkhead Transcription Factors - antagonists &amp; inhibitors ; Forkhead Transcription Factors - biosynthesis ; Forkhead Transcription Factors - genetics ; Gene Expression Profiling ; Gene Knockdown Techniques ; HEK293 Cells ; Humans ; Immunohistochemistry ; Infant ; Medical sciences ; Medulloblastoma - genetics ; Medulloblastoma - metabolism ; Medulloblastoma - pathology ; Middle Aged ; Neoplasm Staging ; Neurology ; Peptides - pharmacology ; Pharmacology. Drug treatments ; Prognosis ; Tumors of the nervous system. Phacomatoses ; Young Adult</subject><ispartof>Clinical cancer research, 2011-11, Vol.17 (21), p.6791-6801</ispartof><rights>2015 INIST-CNRS</rights><rights>2011 AACR</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-af8954509345b45dcfacb7b011cf2a29d3f8e53b3d9cd42a211df62e0a593f933</citedby><cites>FETCH-LOGICAL-c451t-af8954509345b45dcfacb7b011cf2a29d3f8e53b3d9cd42a211df62e0a593f933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24724192$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21918172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PRILLER, Markus</creatorcontrib><creatorcontrib>PÖSCHL, Julia</creatorcontrib><creatorcontrib>ABRAO, Leticia</creatorcontrib><creatorcontrib>VON BUEREN, André O</creatorcontrib><creatorcontrib>CHO, Yoon-Jae</creatorcontrib><creatorcontrib>RUTKOWSKI, Stefan</creatorcontrib><creatorcontrib>KRETZSCHMAR, Hans A</creatorcontrib><creatorcontrib>SCHÜLLER, Ulrich</creatorcontrib><title>Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>The transcription factor Forkhead box M1 (FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P = 0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. FoxM1 may be used as an additional prognostic marker and may represent a potential novel target to treat patients suffering from medulloblastoma.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cell Growth Processes - physiology</subject><subject>Cell Line, Tumor</subject><subject>Cerebellar Neoplasms - genetics</subject><subject>Cerebellar Neoplasms - metabolism</subject><subject>Cerebellar Neoplasms - pathology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Forkhead Box Protein M1</subject><subject>Forkhead Transcription Factors - antagonists &amp; inhibitors</subject><subject>Forkhead Transcription Factors - biosynthesis</subject><subject>Forkhead Transcription Factors - genetics</subject><subject>Gene Expression Profiling</subject><subject>Gene Knockdown Techniques</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Infant</subject><subject>Medical sciences</subject><subject>Medulloblastoma - genetics</subject><subject>Medulloblastoma - metabolism</subject><subject>Medulloblastoma - pathology</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Neurology</subject><subject>Peptides - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Tumors of the nervous system. Phacomatoses</subject><subject>Young Adult</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtP3TAQRi0EAgr9CSBvUFehHj9IvKwiaK8EKqJFXVqOHyLIN754Eh7_vom4tKsZjc43MzqEnAA7B1DNV2B1UzEp-LlzpQKogIPcIYegVF0JfqF25_6DOSCfEB8ZAwlM7pMDDhoaqPkhebl83ZSA2OeB5kiv8usN0BXSu_A09SV4GnOh40OgtyWnPoZixy16E_yUUu6SxTGvLW1DSkjt4Olq8L2zY0D6JxcM9NdUnvtnm5bU7ZwPw4jHZC_ahOHzth6R-6vL3-2P6vrn91X77bpyUsFY2dhoJRXTQqpOKu-idV3dMQAXueXai9gEJTrhtfNyngD4eMEDs0qLqIU4Il_e925KfpoCjmbdo5tftUPIExrNOGtUw_hMqnfSlYxYQjSb0q9teTPAzKLcLDrNotO07d08MovyOXe6vTB16-D_pT4cz8DZFrDobIrFDq7H_5ysuQTNxV-3J4sI</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>PRILLER, Markus</creator><creator>PÖSCHL, Julia</creator><creator>ABRAO, Leticia</creator><creator>VON BUEREN, André O</creator><creator>CHO, Yoon-Jae</creator><creator>RUTKOWSKI, Stefan</creator><creator>KRETZSCHMAR, Hans A</creator><creator>SCHÜLLER, Ulrich</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111101</creationdate><title>Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients</title><author>PRILLER, Markus ; PÖSCHL, Julia ; ABRAO, Leticia ; VON BUEREN, André O ; CHO, Yoon-Jae ; RUTKOWSKI, Stefan ; KRETZSCHMAR, Hans A ; SCHÜLLER, Ulrich</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-af8954509345b45dcfacb7b011cf2a29d3f8e53b3d9cd42a211df62e0a593f933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cell Growth Processes - physiology</topic><topic>Cell Line, Tumor</topic><topic>Cerebellar Neoplasms - genetics</topic><topic>Cerebellar Neoplasms - metabolism</topic><topic>Cerebellar Neoplasms - pathology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Forkhead Box Protein M1</topic><topic>Forkhead Transcription Factors - antagonists &amp; inhibitors</topic><topic>Forkhead Transcription Factors - biosynthesis</topic><topic>Forkhead Transcription Factors - genetics</topic><topic>Gene Expression Profiling</topic><topic>Gene Knockdown Techniques</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Infant</topic><topic>Medical sciences</topic><topic>Medulloblastoma - genetics</topic><topic>Medulloblastoma - metabolism</topic><topic>Medulloblastoma - pathology</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Neurology</topic><topic>Peptides - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Tumors of the nervous system. Phacomatoses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PRILLER, Markus</creatorcontrib><creatorcontrib>PÖSCHL, Julia</creatorcontrib><creatorcontrib>ABRAO, Leticia</creatorcontrib><creatorcontrib>VON BUEREN, André O</creatorcontrib><creatorcontrib>CHO, Yoon-Jae</creatorcontrib><creatorcontrib>RUTKOWSKI, Stefan</creatorcontrib><creatorcontrib>KRETZSCHMAR, Hans A</creatorcontrib><creatorcontrib>SCHÜLLER, Ulrich</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PRILLER, Markus</au><au>PÖSCHL, Julia</au><au>ABRAO, Leticia</au><au>VON BUEREN, André O</au><au>CHO, Yoon-Jae</au><au>RUTKOWSKI, Stefan</au><au>KRETZSCHMAR, Hans A</au><au>SCHÜLLER, Ulrich</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>17</volume><issue>21</issue><spage>6791</spage><epage>6801</epage><pages>6791-6801</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><abstract>The transcription factor Forkhead box M1 (FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P = 0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. FoxM1 may be used as an additional prognostic marker and may represent a potential novel target to treat patients suffering from medulloblastoma.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>21918172</pmid><doi>10.1158/1078-0432.ccr-11-1214</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2011-11, Vol.17 (21), p.6791-6801
issn 1078-0432
1557-3265
language eng
recordid cdi_proquest_miscellaneous_902085802
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adolescent
Adult
Antineoplastic agents
Biological and medical sciences
Biomarkers, Tumor - biosynthesis
Biomarkers, Tumor - genetics
Cell Growth Processes - physiology
Cell Line, Tumor
Cerebellar Neoplasms - genetics
Cerebellar Neoplasms - metabolism
Cerebellar Neoplasms - pathology
Child
Child, Preschool
Forkhead Box Protein M1
Forkhead Transcription Factors - antagonists & inhibitors
Forkhead Transcription Factors - biosynthesis
Forkhead Transcription Factors - genetics
Gene Expression Profiling
Gene Knockdown Techniques
HEK293 Cells
Humans
Immunohistochemistry
Infant
Medical sciences
Medulloblastoma - genetics
Medulloblastoma - metabolism
Medulloblastoma - pathology
Middle Aged
Neoplasm Staging
Neurology
Peptides - pharmacology
Pharmacology. Drug treatments
Prognosis
Tumors of the nervous system. Phacomatoses
Young Adult
title Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A29%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20FoxM1%20Is%20Required%20for%20the%20Proliferation%20of%20Medulloblastoma%20Cells%20and%20Indicates%20Worse%20Survival%20of%20Patients&rft.jtitle=Clinical%20cancer%20research&rft.au=PRILLER,%20Markus&rft.date=2011-11-01&rft.volume=17&rft.issue=21&rft.spage=6791&rft.epage=6801&rft.pages=6791-6801&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/10.1158/1078-0432.ccr-11-1214&rft_dat=%3Cproquest_cross%3E902085802%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=902085802&rft_id=info:pmid/21918172&rfr_iscdi=true